Zoledronate

ApprovedSmall molecule

Mario Negri Institute for Pharmacological Research

Zoledronate is one of 205 small molecule programs targeting Liver Transplant. It is currently in Approved.

Indications

Total Trials

Active Trials

204

Competitors

Pipeline

Status by Indication[3][1]

Indication

Liver TransplantActive, not recruiting

Hip FractureActive, not recruiting

Cervical Intraepithelial NeoplasiaActive, not recruiting

Breast CancerActive, not recruiting

Renal Cell CarcinomaActive, not recruiting

Multiple MyelomaActive, not recruiting

OsteoporosisActive, not recruiting

Early-Stage Breast CancerCompleted

Liver TransplantPreclinical

Active, not recruiting

Hip FractureApproved

Active, not recruiting

Cervical Intraepithelial NeoplasiaPhase 1

Active, not recruiting

Breast CancerPhase 2

Active, not recruiting

Renal Cell CarcinomaPhase 2

Active, not recruiting

Multiple MyelomaPhase 3

Active, not recruiting

OsteoporosisApproved

Active, not recruiting

Early-Stage Breast CancerApproved

Completed

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Zoledronate

Mario Negri Institute for Pharmacological Research

Approved

4 2

DATROWAY

Daiichi Sankyo

Preclinical

4 3

Apatinib Mesylate

BBukwang Pharmaceutical

Preclinical

3 4

Perflutren Lipid Microsphere

IImaRx Therapeutics

Preclinical

1 5

Diuretic

RReprieve Cardiovascular, Inc

Preclinical

1 6

Recombinant Human Endostatin

PPeking University Third Hospital

Preclinical

1 7

Conventional Chemotherapy

SShanghai Jiao Tong University School of Medicine

Preclinical

1 8

Motexafin Gadolinium

PPharmacyclics LLC.

Preclinical

1 9

Metfomin

UUniversity of Texas Southwestern Medical Center

Preclinical

1 10

Tianeptine

Pfizer

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Post-ApprovalActive, not recruiting

Osteoporosis

NCT05655013

Q2 2027

Recruiting

Treatment

NCT06164795

Q4 2027

Phase 1Recruiting

Hematologic Malignancies

NCT02508038

Q4 2028

Phase 1Recruiting

Complication

NCT07375290

Post-ApprovalRecruiting

Osteoporosis

NCT07281586

Clinical

Trials by Indication[1]

Breast Cancer4 trials

Bone Mineral Density Effects of Zoledronate in Postmenopausal Women With Breast Cancer

Completed·UUniversity of Wisconsin, Madison·Phase 2·NCT00213980·68 enrolled

Pre-operative Zoledronate in Triple Negative Breast Cancer

Terminated· Mario Negri Institute for Pharmacological Research logo

Mario Negri Institute for Pharmacological Research·Phase 2·NCT02347163·22 enrolled

Neoadjuvant Zoledronate and Atorvastatin in Triple Negative Breast Cancer

Completed· Mario Negri Institute for Pharmacological Research logo

Mario Negri Institute for Pharmacological Research·Phase 2·NCT03358017·54 enrolled

Show 1 more trial

S0308 Zoledronate or Ibandronate in Preventing Bone Problems in Women With Stage IV Breast Cancer That Has Spread to the Bone

Withdrawn·SSWOG Cancer Research Network·Phase 3·NCT00301886

Osteoporosis3 trials

Treatment With Zoledronate Subsequent to Denosumab in Osteoporosis 2 (ZOLARMAB2)

Active, not recruiting·—·Phase 4·NCT05655013·200 enrolled

Step-down Therapy After Long-term Osteoporosis Treatment

Recruiting·NNational Taiwan University Hospital·Phase 4·NCT07281586·44 enrolled

The Optimised Use of Romozosumab Study

Recruiting·UUniversity of Aarhus·Approved·NCT06059222·270 enrolled

Treatment3 trials

The Optimal Sequential Therapy After Long Term Denosumab Treatment

Completed·NNational Taiwan University Hospital·Phase 4·NCT05091099·44 enrolled

Sequential Therapies After Osteoanabolic Treatment

Recruiting·—··NCT06164795·150 enrolled

Bone Loss Treatment From Adjuvant Zoledronate Efficacy

Terminated·FFirst Affiliated Hospital, Sun Yat-Sen University·N/A·NCT01623908·200 enrolled

Bone Metastases1 trial

4-weekly Versus 12-weekly Administration of Bone-targeted Agents in Patients With Bone Metastases

Completed·OOttawa Hospital Research Institute·Phase 4·NCT02721433·263 enrolled

Hip Fracture1 trial

The Effect of Zoledronate on the Prevention of Pneumonia in Hip Fracture Patients

Unknown status·TThe University of Hong Kong·Phase 4·NCT05743179·2,692 enrolled

10 more indications

Liver Transplant1 trial

Use of Bisphosphonates in the Treatment of Osteopathy After Liver Transplantation

Unknown status·MMedical University of Vienna·N/A·NCT00302484·96 enrolled

Vertebroplasty1 trial

Denosumab vs Zoledronate After Vertebroplasty

Completed·SShenzhen People's Hospital·Phase 4·NCT05598606·75 enrolled

Adult1 trial

Bisphosphonate Therapy for HIV-Infected Adults With Decreased Bone Mineral Density

Unknown status·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00102908·30 enrolled

Cervical Intraepithelial Neoplasia1 trial

Zoledronate in Treating Patients With Cervical Intraepithelial Neoplasia 2/3 or 3

Terminated·UUniversity of California, San Francisco·Phase 1·NCT00278434·12 enrolled

Complication1 trial

Zoledronate to Prevent Bone Health Complications in Pediatric Hematopoietic Stem Cell Transplant Survivors

Recruiting·—·Phase 1·NCT07375290·20 enrolled

Hematologic Malignancies1 trial

Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors

Recruiting·UUniversity of Wisconsin, Madison·Phase 1·NCT02508038·22 enrolled

Renal Cell Carcinoma1 trial

Zoledronate With Atorvastatin in Renal Cell Carcinoma

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00490698·11 enrolled

Multiple Myeloma1 trial

Comparison of Ibandronate - Zoledronate Regarding Nephrotoxicity in Multiple Myeloma

Terminated· Roche logo

Roche·Phase 3·NCT02739594·89 enrolled

Early-stage Breast Cancer1 trial

A Randomised, Multicentre, Pragmatic Trial Comparing a Single-Dose vs. Twice Yearly Zoledronate in Patients With Early Stage Breast Cancer (REaCT-ZOL)

Completed·OOttawa Hospital Research Institute·Approved·NCT03664687·211 enrolled

Unspecified1 trial

Denosumab vs Zoledronate After Lumbar Fusion

Unknown status·SShenzhen People's Hospital·Phase 3·NCT05638399·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 22 trial records for Zoledronate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Zoledronate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Zoledronate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Mario Negri Institute for Pharmacological Research company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Mario Negri Institute for Pharmacological Research

Zoledronate

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q2 2027

Q4 2027

Q4 2028

Trials by Indication[1]

Breast Cancer4 trials

Osteoporosis3 trials

Treatment3 trials

Bone Metastases1 trial

Hip Fracture1 trial

Liver Transplant1 trial

Vertebroplasty1 trial

Adult1 trial

Cervical Intraepithelial Neoplasia1 trial

Complication1 trial

Hematologic Malignancies1 trial

Renal Cell Carcinoma1 trial

Multiple Myeloma1 trial

Early-stage Breast Cancer1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News